Candesartan
- Generic Name
- Candesartan
- Brand Names
- Atacand, Atacand Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H20N6O3
- CAS Number
- 139481-59-7
- Unique Ingredient Identifier
- S8Q36MD2XX
- Background
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.
- Indication
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...
- Associated Conditions
- Hypertension, NYHA Functional Class II-IV Heart Failure
- Associated Therapies
- -
Effect of Some Drugs on Liver Fibrosis
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2018-12-10
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 45
- Registration Number
- NCT03770936
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Candesartan in Peripheral Neuropathy
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 9
- Registration Number
- NCT03688633
- Locations
- 🇫🇷
CHU Limoges, Limoges, France
Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 62
- Registration Number
- NCT03640312
- Locations
- 🇺🇸
ACCESS Martin T. Russo Family Health Center, Bloomingdale, Illinois, United States
🇺🇸Ashland Family Health Center, Chicago, Illinois, United States
Adiposity and Endothelin Receptor Function
- Conditions
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 25
- Registration Number
- NCT03583866
- Locations
- 🇺🇸
Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology, Augusta, Georgia, United States
Bariatric Surgery and Pharmacokinetics of Candesartan
- Conditions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03460327
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Expression and Function of the Renin-Angiotensin System in the Esophagus
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 33
- Registration Number
- NCT02879721
- Locations
- 🇸🇪
Dept. of Gastrosurgical Research and Education, Inst. Clinical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden
DP-R208 Pharmacokinetic Study
- Conditions
- Interventions
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 37
- Registration Number
- NCT02709187
Clinical Trial to Compare the Pharmacokinetics of DP-R208
- Conditions
- Interventions
- First Posted Date
- 2016-03-14
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Alvogen Korea
- Target Recruit Count
- 40
- Registration Number
- NCT02707224
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 77
- Registration Number
- NCT02646982
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Wesley Woods Center, Atlanta, Georgia, United States
Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects
- Conditions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT02609711
- Locations
- 🇰🇷
Inha Univ. Hospital, Incheon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.